The drug biologies are not completely unlinked: a previous study showed that camptothecin sensitivity (including irinotecan) is determined by PLK1 expression in squamous cell carcinoma, and that combined treatment of irinotecan and the PLK1 inhibitor BI2536 increased the antitumor effect of irinotecan [48]. Here, PLK1 is linked to squamous cell carcinoma.